Related Experiment Video
Updated: Dec 17, 2025

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through
Antonia Kefala Stavridi1, Robert Appleby1, Shikang Liang1
1Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB21GA, Cambridgeshire, U.K.
Abstract:
Non-homologous end joining (NHEJ) is one of the two principal damage repair pathways for DNA double-strand breaks in cells. In this review, we give a brief overview of the system including a discussion of the effects of deregulation of NHEJ components in carcinogenesis and resistance to cancer therapy. We then discuss the relevance of targeting NHEJ components pharmacologically as a potential cancer therapy and review previous approaches to orthosteric regulation of NHEJ factors. Given the limited success of previous investigations to develop inhibitors against individual components, we give a brief discussion of the recent advances in computational and structural biology that allow us to explore different targets, with a particular focus on modulating protein-protein interaction interfaces. We illustrate this discussion with three examples showcasing some current approaches to developing protein-protein interaction inhibitors to modulate the assembly of NHEJ multiprotein complexes in space and time.
Insights
Non-homologous end joining (NHEJ) repairs DNA double-strand breaks. Targeting NHEJ components offers potential cancer therapies, especially by modulating protein-protein interactions, overcoming limitations of earlier drug development approaches.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- Non-homologous end joining (NHEJ) is a critical DNA repair pathway for double-strand breaks.
- Dysregulation of NHEJ components is implicated in cancer development and treatment resistance.
Purpose of the Study:
- To review the role of NHEJ in cancer and its therapeutic potential.
- To explore novel strategies for targeting NHEJ, focusing on protein-protein interactions.
Main Methods:
- Review of existing literature on NHEJ pathways and cancer therapy.
- Discussion of computational and structural biology advancements.
- Analysis of protein-protein interaction inhibitor strategies.
Main Results:
- NHEJ deregulation contributes to carcinogenesis and therapy resistance.
- Targeting NHEJ offers a promising avenue for cancer treatment.
- Modulating protein-protein interactions presents a novel approach to inhibit NHEJ complex assembly.
Conclusions:
- Pharmacological targeting of NHEJ components, particularly via protein-protein interactions, is a viable strategy for cancer therapy.
- Advances in computational biology enable exploration of new therapeutic targets within NHEJ pathways.
Related Concept Videos
Fixing Double-strand Breaks
Fixing Double-strand Breaks
Homologous Recombination
Long-patch Base Excision Repair
Single-Strand DNA Binding Proteins
Base-pairing and DNA Repair

